Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in Bariatric and Gallstone Disease
NCT01625026Phase 2Completed
- Sponsor
- Sahlgrenska University Hospital
- Start
- Sep 2013
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obeticholic acid in obesity and cholelithiasis (4 arms), sponsored by Sahlgrenska University Hospital. Primary endpoint: Effects of OCA on FXR-dependent metabolism at Day 21. Started Sep 2013; status: completed.
02
Drugs
obeticholic acid
03
Conditions
obesitycholelithiasis
Beyond the preview
Go deeper on NCT01625026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625026.